(NASDAQ: SAGE) Sage Therapeutics's forecast annual revenue growth rate of 51.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.89%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.67%.
Sage Therapeutics's revenue in 2025 is $47,404,000.On average, 8 Wall Street analysts forecast SAGE's revenue for 2025 to be $5,140,658,012, with the lowest SAGE revenue forecast at $4,065,335,454, and the highest SAGE revenue forecast at $8,134,428,151. On average, 8 Wall Street analysts forecast SAGE's revenue for 2026 to be $7,878,497,374, with the lowest SAGE revenue forecast at $5,009,655,520, and the highest SAGE revenue forecast at $11,847,835,305.
In 2027, SAGE is forecast to generate $10,299,851,749 in revenue, with the lowest revenue forecast at $7,430,571,550 and the highest revenue forecast at $13,388,304,377.